At least 400 million doses of the Oxford and Pomezia vaccine will be ready in September. The multinational AstraZeneca has signed the first production agreements, but announces that it is working on arrangements with several European governments at the same time. The USA is also joining the vaccine development team and Italian company IRBM, based in Pomezia (Rome), is collaborating with Oxford. Phase 1-2 of the trial is underway to assess safety, immunogenicity and efficacy of the potential vaccine.
Article published on Il Mattino – 21/05/2020
Read the original article on ilmattino.it